vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and BLACKBERRY Ltd (BB). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $141.8M, roughly 1.3× BLACKBERRY Ltd). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 9.7%, a 3.7% gap on every dollar of revenue. On growth, BLACKBERRY Ltd posted the faster year-over-year revenue change (-0.8% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $17.4M). Over the past eight quarters, BLACKBERRY Ltd's revenue compounded faster (17.8% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
BlackBerry Limited, formerly Research In Motion (RIM), is a Canadian software company specializing in secure communications and the Internet of Things (IoT). Founded in 1984, it developed the BlackBerry brand of two-way pagers, smartphones, and tablets. The company later transitioned to providing software and services and holds critical software application patents.
AMPH vs BB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $141.8M |
| Net Profit | $24.4M | $13.7M |
| Gross Margin | 46.8% | 77.5% |
| Operating Margin | 19.4% | 8.4% |
| Net Margin | 13.3% | 9.7% |
| Revenue YoY | -1.8% | -0.8% |
| Net Profit YoY | -35.7% | 224.5% |
| EPS (diluted) | $0.51 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $141.8M | ||
| Q3 25 | $191.8M | $129.6M | ||
| Q2 25 | $174.4M | $121.7M | ||
| Q1 25 | $170.5M | $141.7M | ||
| Q4 24 | $186.5M | $143.6M | ||
| Q3 24 | $191.2M | $126.2M | ||
| Q2 24 | $182.4M | $123.4M | ||
| Q1 24 | $171.8M | $102.1M |
| Q4 25 | $24.4M | $13.7M | ||
| Q3 25 | $17.4M | $13.3M | ||
| Q2 25 | $31.0M | $1.9M | ||
| Q1 25 | $25.3M | $-7.4M | ||
| Q4 24 | $38.0M | $-10.5M | ||
| Q3 24 | $40.4M | $-19.7M | ||
| Q2 24 | $37.9M | $-41.4M | ||
| Q1 24 | $43.2M | $-56.2M |
| Q4 25 | 46.8% | 77.5% | ||
| Q3 25 | 51.4% | 74.5% | ||
| Q2 25 | 49.6% | 74.2% | ||
| Q1 25 | 50.0% | 73.5% | ||
| Q4 24 | 46.5% | 78.1% | ||
| Q3 24 | 53.3% | 70.2% | ||
| Q2 24 | 52.2% | 72.9% | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 8.4% | ||
| Q3 25 | 13.2% | 8.9% | ||
| Q2 25 | 24.2% | 1.6% | ||
| Q1 25 | 21.9% | -5.6% | ||
| Q4 24 | 24.2% | 13.6% | ||
| Q3 24 | 29.8% | 1.7% | ||
| Q2 24 | 30.3% | -10.5% | ||
| Q1 24 | 27.9% | 50.0% |
| Q4 25 | 13.3% | 9.7% | ||
| Q3 25 | 9.0% | 10.3% | ||
| Q2 25 | 17.8% | 1.6% | ||
| Q1 25 | 14.8% | -5.2% | ||
| Q4 24 | 20.4% | -7.3% | ||
| Q3 24 | 21.1% | -15.6% | ||
| Q2 24 | 20.8% | -33.5% | ||
| Q1 24 | 25.1% | -55.0% |
| Q4 25 | $0.51 | $0.02 | ||
| Q3 25 | $0.37 | $0.02 | ||
| Q2 25 | $0.64 | $0.00 | ||
| Q1 25 | $0.51 | $-0.01 | ||
| Q4 24 | $0.74 | $-0.02 | ||
| Q3 24 | $0.78 | $-0.03 | ||
| Q2 24 | $0.73 | $-0.07 | ||
| Q1 24 | $0.81 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $304.2M |
| Total DebtLower is stronger | $608.7M | $196.2M |
| Stockholders' EquityBook value | $788.8M | $741.1M |
| Total Assets | $1.6B | $1.2B |
| Debt / EquityLower = less leverage | 0.77× | 0.26× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $304.2M | ||
| Q3 25 | $276.2M | $290.5M | ||
| Q2 25 | $231.8M | $306.6M | ||
| Q1 25 | $236.9M | $337.8M | ||
| Q4 24 | $221.6M | $220.0M | ||
| Q3 24 | $250.5M | $211.0M | ||
| Q2 24 | $217.8M | $229.0M | ||
| Q1 24 | $289.6M | $237.1M |
| Q4 25 | $608.7M | $196.2M | ||
| Q3 25 | $608.6M | $195.9M | ||
| Q2 25 | $607.7M | $195.6M | ||
| Q1 25 | $603.9M | $195.3M | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | $194.1M |
| Q4 25 | $788.8M | $741.1M | ||
| Q3 25 | $776.7M | $725.1M | ||
| Q2 25 | $757.5M | $725.1M | ||
| Q1 25 | $751.3M | $719.9M | ||
| Q4 24 | $732.3M | $725.2M | ||
| Q3 24 | $727.7M | $732.1M | ||
| Q2 24 | $713.3M | $742.6M | ||
| Q1 24 | $672.4M | $775.1M |
| Q4 25 | $1.6B | $1.2B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.5B | $1.3B | ||
| Q2 24 | $1.5B | $1.3B | ||
| Q1 24 | $1.6B | $1.4B |
| Q4 25 | 0.77× | 0.26× | ||
| Q3 25 | 0.78× | 0.27× | ||
| Q2 25 | 0.80× | 0.27× | ||
| Q1 25 | 0.80× | 0.27× | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | 0.25× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $18.3M |
| Free Cash FlowOCF − Capex | $24.6M | $17.4M |
| FCF MarginFCF / Revenue | 13.4% | 12.3% |
| Capex IntensityCapex / Revenue | 4.5% | 0.6% |
| Cash ConversionOCF / Net Profit | 1.35× | 1.34× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $42.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $18.3M | ||
| Q3 25 | $52.6M | $3.9M | ||
| Q2 25 | $35.6M | $-18.0M | ||
| Q1 25 | $35.1M | $41.6M | ||
| Q4 24 | $29.0M | $6.0M | ||
| Q3 24 | $60.0M | $-16.0M | ||
| Q2 24 | $69.1M | $-15.1M | ||
| Q1 24 | $55.3M | $-15.5M |
| Q4 25 | $24.6M | $17.4M | ||
| Q3 25 | $47.2M | $3.1M | ||
| Q2 25 | $25.0M | $-18.9M | ||
| Q1 25 | $24.4M | $41.2M | ||
| Q4 24 | $16.6M | $5.2M | ||
| Q3 24 | $46.2M | $-16.5M | ||
| Q2 24 | $63.1M | $-16.5M | ||
| Q1 24 | $46.5M | $-17.6M |
| Q4 25 | 13.4% | 12.3% | ||
| Q3 25 | 24.6% | 2.4% | ||
| Q2 25 | 14.3% | -15.5% | ||
| Q1 25 | 14.3% | 29.1% | ||
| Q4 24 | 8.9% | 3.6% | ||
| Q3 24 | 24.1% | -13.1% | ||
| Q2 24 | 34.6% | -13.4% | ||
| Q1 24 | 27.1% | -17.2% |
| Q4 25 | 4.5% | 0.6% | ||
| Q3 25 | 2.8% | 0.6% | ||
| Q2 25 | 6.1% | 0.7% | ||
| Q1 25 | 6.3% | 0.3% | ||
| Q4 24 | 6.7% | 0.6% | ||
| Q3 24 | 7.2% | 0.4% | ||
| Q2 24 | 3.3% | 1.1% | ||
| Q1 24 | 5.1% | 2.1% |
| Q4 25 | 1.35× | 1.34× | ||
| Q3 25 | 3.03× | 0.29× | ||
| Q2 25 | 1.15× | -9.47× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
BB
| QNX | $68.7M | 48% |
| Secure Communication | $67.0M | 47% |
| Licensing | $6.1M | 4% |
